- Home
- IMRN vs NRXP Comparison
IMRN vs NRXP Comparison
Compare IMRN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- NRXP
- Stock Information
- Founded
- IMRN 1994
- NRXP 2015
- Country
- IMRN Australia
- NRXP United States
- Employees
- IMRN N/A
- NRXP N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- NRXP Health Care
- Exchange
- IMRN Nasdaq
- NRXP Nasdaq
- Market Cap
- IMRN 15.0M
- NRXP 14.8M
- IPO Year
- IMRN N/A
- NRXP N/A
- Fundamental
- Price
- IMRN $2.11
- NRXP $1.52
- Analyst Decision
- IMRN Strong Buy
- NRXP Strong Buy
- Analyst Count
- IMRN 1
- NRXP 3
- Target Price
- IMRN $5.00
- NRXP $31.67
- AVG Volume (30 Days)
- IMRN 6.2K
- NRXP 288.4K
- Earning Date
- IMRN 12-31-2024
- NRXP 11-14-2024
- Dividend Yield
- IMRN N/A
- NRXP N/A
- EPS Growth
- IMRN N/A
- NRXP N/A
- EPS
- IMRN N/A
- NRXP N/A
- Revenue
- IMRN $3,271,194.00
- NRXP N/A
- Revenue This Year
- IMRN N/A
- NRXP N/A
- Revenue Next Year
- IMRN N/A
- NRXP N/A
- P/E Ratio
- IMRN N/A
- NRXP N/A
- Revenue Growth
- IMRN 171.67
- NRXP N/A
- 52 Week Low
- IMRN $1.59
- NRXP $1.10
- 52 Week High
- IMRN $5.96
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- IMRN 52.87
- NRXP 66.79
- Support Level
- IMRN $2.05
- NRXP $1.17
- Resistance Level
- IMRN $2.23
- NRXP $1.23
- Average True Range (ATR)
- IMRN 0.16
- NRXP 0.11
- MACD
- IMRN 0.02
- NRXP 0.04
- Stochastic Oscillator
- IMRN 47.06
- NRXP 58.57
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.